Conexão rápida Enviar uma mensagem
In a latest development, Emergency use approval has been granted in India for anti – COVID-19 therapeutic application of the key Active Pharmaceutical Ingredient, 2-deoxy-D-glucose ( 2DG) developed by INMAS, a lab of DRDO, in collaboration with Dr. Reddy’s laboratories.
Deepak Sapra, CEO, API e Serviços, falou com ANI notícias em 17 de maio de 2021, e esclareceu que 2DG é uma droga antiviral oral que pode ser administrada apenas sob prescrição para pacientes com COVID-19 moderado a severo como terapia adjunta (somada) ao padrão de tratamento existente.Ele disse que a droga anti-COVID 2-DG de DRDO é um adicional, não um substituto para outras medicações.Clique aqui para ler a resposta completa.
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.
+91 4049002253